Monday, June 8, 2020


PRTO Proteon Therapeutics, Inc. gains 95% Jun 5, 2020

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in two Phase III clinical trials in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis; has completed a Phase I/II clinical trials for the treatment of patients undergoing arteriovenous graft placement; and has completed Phase I clinical trial for the treatment of symptomatic peripheral artery diseases. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive